Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:33 AM
Ignite Modification Date: 2025-12-25 @ 3:33 AM
NCT ID: NCT01657305
Eligibility Criteria: Inclusion Criteria: * Presenting a split-thickness skin graft donor site wound with a minimum size of 15 cm2 and with a minimum width of 3 cm. * Patient is able to understand the Informed Consent Form (ICF) provided and is prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing change and photo documentation every third or fourth day until both wound halves are closed (but no longer than 28 days after surgery). * Willing to perform all necessary wound dressing changes at the trial site. Also the patient needs to agree to return to site for 3 and 12 months follow-up visits. * Women of childbearing potential must apply highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner)). Exclusion Criteria: * Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety or efficacy. * A skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial. * A history of clinically significant hypersensitivity to any of the drugs, surgical dressings or excipients to be used in this trial. * Known multiple allergic disorders. * Taking, or have taken, any investigational drugs within 3 months prior to the screening visit. * Pregnant or breast feeding women are not allowed to participate in the study. * Inappropriate to participate in the study, for any reason, in the opinion of the investigator. * Mental incapacity or language barriers precluding adequate understanding the Informed consent form or co-operation or willingness to follow study procedures. * Previous participation in this study. * Employee at the investigational site, relative or spouse of the investigator.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT01657305
Study Brief:
Protocol Section: NCT01657305